Hanken Henning, Gaudin Robert, Gröbe Alexander, Fraederich Meike, Eichhorn Wolfgang, Smeets Ralf, Simon Ronald, Sauter Guido, Grupp Katharina, Izbicki Jacob R, Sehner Susanne, Heiland Max, Blessmann Marco
Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
J Oral Pathol Med. 2014 Apr;43(4):304-8. doi: 10.1111/jop.12173. Epub 2014 Mar 20.
Her2 (ErbB2) transforms cells when overexpressed and is an important therapeutic target in breast cancer. Contrary to breast cancer, studies on Her2 overexpression and gene amplification in squamous cell carcinomas of the head and neck region described largely different results. This study was undertaken to learn more on the prevalence and clinical significance of HER2 amplification and overexpression in squamous cell carcinomas of the head and neck.
Her2 expression and gene amplification was analyzed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) on two tissue microarrays composed of 427 squamous cell carcinomas of the head and neck region and 222 oral squamous cell carcinomas. Results were compared with clinicopathological features.
Her2 expression and gene amplification was rarely detectable in squamous cell carcinomas of the head and neck region and unrelated to tumor phenotype or survival of the patients with oral squamous carcinoma.
Our results demonstrate that Her2 protein and gene amplification was only detectable in a small subset of squamous cell carcinomas of the head and neck region as well as oral squamous cell carcinomas. However, it can be speculated that those few patients with Her2 overexpressing and gene amplificated tumors may possibly benefit from an anti-Her2 therapy.
Her2（ErbB2）过度表达时可使细胞发生转化，是乳腺癌重要的治疗靶点。与乳腺癌不同，关于头颈部鳞状细胞癌中Her2过表达和基因扩增的研究结果差异较大。本研究旨在进一步了解头颈部鳞状细胞癌中HER2扩增和过表达的发生率及其临床意义。
采用免疫组织化学（IHC）和荧光原位杂交（FISH）技术，对由427例头颈部鳞状细胞癌和222例口腔鳞状细胞癌组成的两个组织芯片进行Her2表达和基因扩增分析。将结果与临床病理特征进行比较。
在头颈部鳞状细胞癌中很少能检测到Her2表达和基因扩增，且与口腔鳞状细胞癌患者的肿瘤表型或生存情况无关。
我们的结果表明，Her2蛋白和基因扩增仅在一小部分头颈部鳞状细胞癌以及口腔鳞状细胞癌中可检测到。然而，可以推测，那些少数Her2过表达和基因扩增肿瘤的患者可能会从抗Her2治疗中获益。
